Retatrutide Reconstitution Calculator

An investigational triple agonist (GIP, GLP-1, glucagon) in phase-3 trials. Not FDA-approved.

Informational only. Not medical advice. Consult a licensed healthcare provider before starting, changing, or stopping any protocol.

Reconstitution calculator

Retatrutide

Syringe type
Your dose
Draw 10 units
That's 0.1 mL of your reconstituted solution · Concentration 5,000 mcg/mL
This vial gives you 20 doses at 500 mcg
010203040506070809010010 units
Math is open source · Educational use only · Not medical advice

About Retatrutide

Investigational drug. Not FDA-approved. Currently in clinical trials.

Retatrutide is an investigational triple agonist activating the GIP, GLP-1, and glucagon receptors — extending the dual-agonist mechanism of tirzepatide with the addition of glucagon receptor activity. A phase-2 trial published in NEJM 2023 showed approximately 24% body weight reduction at 48 weeks on the highest dose (12 mg/week). Phase-3 trials (TRIUMPH program) are ongoing through 2026.

Half-life is approximately 5.5 days (132 hours). Trial dose range is 0.5 mg to 12 mg weekly, with titration over 4–12 weeks. Retatrutide is NOT FDA-approved; the only legitimate sources are clinical trials. Compounded or gray-market preparations exist outside the regulatory framework and users are responsible for knowing the legal status in their jurisdiction.

Frequently asked questions

Why is retatrutide called a "triple agonist"?
It activates three receptors — GIP, GLP-1, and glucagon — whereas semaglutide is single (GLP-1 only) and tirzepatide is dual (GIP + GLP-1). The glucagon receptor addition is hypothesized to contribute to energy expenditure effects.
When will retatrutide be FDA-approved?
Phase-3 trials are running through 2026. An FDA approval decision is anticipated sometime in 2027–2028 depending on trial outcomes. No official timeline is published.
Is retatrutide available legally?
The only legitimate access to retatrutide is through enrollment in a clinical trial. Compounded or research-chemical sources exist but operate outside the FDA framework. This app does not source, verify, or endorse any supplier.

Sources

  1. Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM. 2023. PMID: 37366325
  2. Rosenstock J, et al. "Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, in People With Type 2 Diabetes." Lancet. 2023. PMID: 37356421

Related calculators

The app runs every compound.

This page runs one. My Pep Calc runs your whole stack — reconstitution math feeds your dose log, which feeds your site rotation map and the half-life chart. First 500 founders get Lifetime Pro for $149.

See the Founders offer →